DEFB125

Across TCGA pan-cancer cohorts, DEFB125 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated DEFB125 data layer compared with 9 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher DEFB125 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DEFB125 expression acts as an unfavorable survival marker.

SCLC and STAD are the cancer types where DEFB125 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.082	0.822	<.001	12	view →
STAD	DFS	Median	All	0.198	0.587	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

DEFB125–SCLC (OS)

Open the SCLC breakdown →